lung cancer, gastric cancer, esophageal cancer, breast cancer, endometrial cancer, cervical cancer, ovarian cancer, pancreatic cancer
Conditions
Interventions
Compression therapy with surgical Gloves all cycle from 30 minutes before administration of taxane therapy to 30 minutes after administration
no preventation
Sponsors
Hitachi general hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients with lung cancer, gastric cancer, esophageal cancer, breast cancer, endometrial cancer, cervical cancer, ovarian cancer, and pancreatic cancer who receive taxane-containing-regimen porfomance status 0-2 patients who do not have latex allergy Taxane naive patients who got written informed consent
Exclusion criteria
Exclusion criteria: patients who have CTCAE more than grade1 neuropathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of taxane-induced peripheral neuropathy grade 2 or higher using the CTCAE version 5.0. | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of peripheral neuropathy grade B,C,D,E using Patient Neurotoxicity Questionnairethe (PNQ). The incidence of skin and nail tissue disorders using the CTCAE version 5.0. Time to skin and nail tissue disorders The incidence of taxane-induced peripheral neuropathy grade 1.3.4 using the CTCAE version 5.0. Time to peripheral neuropathy Ratio of cases dropping out | — |
Countries
Japan
Contacts
Public ContactTakuya Suyama
Hitachi general hospital hematology,oncology
Outcome results
None listed